@article{92a83a341b0e4ddab026e92fc3a1a22d,
title = "Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab",
keywords = "B lymphocyte receptor, idelalisib, rituximab, allogeneic stem cell transplantation, cancer growth, cancer staging, chronic lymphatic leukemia, clinical outcome, follow up, human, Letter, multivariate logistic regression analysis, overall survival, patient coding, predictive value, risk algorithm, scoring system, survival analysis, univariate analysis, validation study",
author = "M. Gentile and E.A. Martino and A. Visentin and M. Coscia and G. Reda and P. Sportoletti and F.R. Mauro and L. Laurenti and M. Varettoni and R. Murru and A. Chiarenza and E. Vigna and F. Mendicino and E. Lucia and S. Bossio and A.G. Recchia and R. Moia and D. Pietrasanta and G. Loseto and U. Consoli and I. Scortechini and F.M. Rossi and A. Zucchetto and H. Al-Janazreh and C. Vitale and G. Tripepi and G. D{\textquoteright}Arrigo and I. Angeletti and R. Bomben and A. Neri and G. Cutrona and G. Fronza and {Di Raimondo}, F. and G. Gaidano and A. Cuneo and R. Fo{\`a} and M. Ferrarini and L. Trentin and V. Gattei and F. Morabito",
note = "Export Date: 15 October 2020",
year = "2020",
doi = "10.1038/s41408-020-00358-3",
language = "English",
volume = "10",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",
}